Lipoprotein lipase (LPL), the rate-limiting enzyme for hydrolysis of plasma lipoprotein triglycerides, is a normal constituent of the arterial wall. We explored whether LPL affects (a) lipoprotein transport across bovine aortic endothelial cells or (b) lipoprotein binding to subendothelial cell matrix (retention). When bovine milk LPL was added to endothelial cell monolayers before addition of "2'I-labeled LDL, LDL transport across the monolayers was unchanged; but, at all concentrations of LDL tested (1-100 jig), LDL retention by the monolayers increased more than fourfold. '251-labeled LDL binding to extracellular matrix increased when LPL was added directly to the matrix or was added to the basolateral side ofthe endothelial cell monolayers. Increased LDL binding required the presence of LPL and was not associated with LDL aggregation. LPL also increased VLDL, but not HDL, retention. Monoclonal anti-LPL IgG decreased both VLDL and LDL retention in the presence of LPL. Lipoprotein transport across the monolayers increased during hydrolysis of VLDL triglyceride (TG). In the presence of LPL and VLDL, VLDL transport across the monolayers increased 18% and LDL transport increased 37%. High molar concentrations of oleic acid to bovine serum albumin (3:1) in the medium increased VLDL transport 30%.
Introduction
Lipoprotein lipase (LPL),' the principal enzyme responsible for hydrolysis of lipoprotein triglyceride (TG), is synthesized primarily in adipocytes and myocytes. LPL is then released into the interstitial space, crosses the endothelial cell barrier, and attaches to heparan sulfate proteoglycans on the luminal surface ofcapillary endothelium. Intravenous injection ofheparin into humans or animals dissociates LPL from this binding site, resulting in LPL activity in postheparin plasma. LPL initiates chylomicron metabolism (1) and conversion of VLDL to LDL (2) . LPL actions, at least in part, regulate HDL levels (3) . LPL activity in postheparin plasma is positively correlated with HDL cholesterol levels in humans (4) . Because HDL levels are inversely related to risk for coronary artery disease, these data suggest that LPL actions on circulating lipoproteins protect against the development of atherosclerosis.
The artery wall has a small amount of LPL activity that is unlikely to be important in plasma lipoprotein regulation. LPL activity in rabbit aortas correlates with the cholesterol content of the arteries (5) . This relationship, in part, led Zilversmit (5) to hypothesize that arterial wall LPL promotes atherosclerosis. The site of arterial LPL synthesis was recently demonstrated. LPL mRNA is in arterial macrophage-derived foam cells (6, 7) ; LPL protein is in similar areas (7) . Some LPL is also found in areas containing smooth muscle cells (7, 8) . LPL is, therefore, a constituent ofthe atherosclerotic plaque. The physiological or pathophysiological role of LPL within the vessel wall is unknown.
A number of steps are required for the pathological effects of LDL on the arterial wall. These include LDL permeation of the endothelial cell barrier, LDL retention in the arterial wall, and LDL modification to more atherogenic forms (9, 10) . Increases in the amounts of LDL involved in any of these steps will, theoretically, increase the rate of formation of atherosclerotic plaques. Some circulating LDL normally cross the endothelial cell barrier (1 1). Most of this LDL travels through the vessel wall and reenters the circulation via the lymphatics ( 12) . LDL, however, is found in atherosclerotic lesions (13) , suggesting that during atherogenesis LDL are trapped in the subendothelial space. Moreover, atherosclerosis-sensitive areas of rabbit arteries retain more plasma LDL than adjacent atherosclerosis-resistant areas (14) . Thus These findings suggest a mechanism for increased LDL retention in atherosclerotic lesions.
Methods
Isolation oflipoproteins and bovine milk LPL. VLDL, LDL, and HDL were isolated from human plasma by sequential isopynic ultracentrifugation (17) . TG and cholesterol measurements were performed using an automated enzymatic analyzer (model ABA 100; Abbott Laboratories, North Chicago, IL). VLDL, LDL, and HDL were radioiodinated using iodine monochloride (18) . "2'I and "3'I not associated with protein were removed by gel filtration using a PD-l0 column (Pharmacia Fine Chemicals, Inc., Piscataway, NJ) followed by dialysis against 150 mM NaCl, 10 mM sodium phosphate, pH 7.4 (PBS). Radioactivity was measured using a gamma counter (model 1274; LKB Instruments, Gaithersburg, MD). Over 90% of VLDL, LDL, and HDL radioactivity was precipitated using 10% TCA. '25I-labeled LDL specific radioactivity was -16,000 cpm/5g; the specific radioactivity of "3'I-labeled VLDL was 8,500 cpm/yg; '231-labeled HDL specific radioactivity was 226,000 cpm/,gg.
LPLwas purified from fresh unpasteurized bovine milk using heparin-agarose(Bio-Rad Laboratories, Richmond, CA) affinitychromatography and the specific activity determined as described previously (15) . At (Fig. 1 A) . But compared with control, LPL-treated monolayers had more '251I-labeled LDL released from the basolateral side of the cells by heparin (Fig. 1 B) . beled LDL in 1 ml of human serum (cholesterol 170 mg/dl) and 0.5 ml of DME-BSA were added to the upper chambers of control and LPL-treated endothelial cell monolayers. After 1 h at 370C, under control conditions (no LPL), < 1% ofthe transported LDL was retained by the matrix. In the presence of LPL, eight times more '25I-labeled LDL was retained (data not shown). Thus, even in the presence of serum and physiological concentrations ofLDL, LPL marked increased LDL retention.
LDL association with extracellular matrix. LDL released from the basolateral side ofendothelial cell monolayers by heparin could include '25I-labeled LDL associated with the filter, the basolateral surface ofthe cells, and the matrix. We therefore assessed whether LPL specifically increased LDL binding to subendothelial matrix. Confluent monolayers ofcultured endothelial cells were incubated in 3 mM EDTA in PBS for 1 h at room temperature. The cells were then removed with a rubber policeman, leaving the subendothelial cell matrix on the filter.
LPL (10 ,tg) was allowed to associate with the matrix for 45 min at 370C. '25I-labeled LDL (3 ,gg) was then incubated for 1 h at 370C with control filters and filters containing LPL. 125I-labeled LDL bound to the matrix was released with heparin-containing buffer. As shown in Figure 2 A, 1.7 ng ofthe added LDL bound to the control matrix, whereas 201 ng of LDL bound to the LPL-treated matrix. A similar experiment was performed using gelatin-fibronectin-treated filters not used for growth of endothelial cells. Therefore, these filters did not contain endothelial cell-derived matrix. LPL-treated filters containing no matrix retained < 1% of the LDL found on LPL-treated filters containing subendothelial cell matrix. The increase in LDL released by heparin from the basolateral side ofendothelial cell monolayers thus was due, at least in part, to increased LPL-mediated LDL association with the matrix. LDL binding to subendothelial matrix of control and LPLtreated monolayers was assessed. '251-labeled LDL (3 ,ug/ml) in DME-BSA was added to the media on the apical side of the cells. After 1 h at 37°C, the cells were washed and removed from the filters using a rubber policeman. In LPL-treated monolayers, 3.4 ± 0.6 ng (mean±SD) of LDL was released by heparin from the residual filter-associated matrix; 0.99±0.05 ng of LDL was released from control monolayers. It should be noted that during removal of the endothelial cells it is likely that some ofthe matrix was also removed from the cells. Nonetheless, LPL treatment caused a more than threefold increase in matrix-associated LDL. LPL addition to the subendothelial space. After cultured monolayers are incubated with LPL, LPL is bound to endothelial cell surfaces and extracellular matrix and is internalized by the cells. In the experiments shown in Fig. 1 , LPL was added to the cells by its inclusion in the upper-chamber medium. Because LPL is synthesized by arterial cells beneath the endothelial layer, a more physiological situation is to add the LPL to the lower, rather than the upper, chamber medium. The data shown in Fig. 2 the experiments shown in Fig. 1 and the greater amounts of LPL increased total LDL retention. Therefore, LDL retention in Figure 1 (Fig. 4 A) . Prebound LPL had no effect on transport of [3H]dextran across the monolayers. This in- tained by endothelial cell monolayers were determined under the conditions described in A. Results shown are mean±SEM of experiments performed in triplicate.
crease in LDL net transport using prebound LPL was blocked by anti-LPL antibodies (Fig. 4 A) (Fig. 4 A) .
To assess whether LDL transport was altered by FFA alone, lipoprotein-containing medium with a 3:1 ratio of oleic acid/ BSA was added to the apical side ofthe cells. Addition of oleic acid increased LDLtransport 41.5% (Fig. 4A, right bar) . Transport of dextran did not increase during these 1-h experiments, suggesting that short-term incubation with oleic acid did not alter the integrity of the monolayer. Therefore, oleic acid and perhaps other VLDL lipolysis products increased LDL transport without damaging endothelial cell monolayers.
A marked increase in '251-labeled LDL retention by the monolayers was found in the presence of LPL. In this experiment, LDL retention increased approximately 8-fold if the LPL was in solution (Fig. 4 B, left bar) and 24-fold if the LPL was first allowed to bind to the cells (Fig. 4 B) . If LPL was first allowed to bind to the cells and then anti-LPL IgG added, the retention of '251I-labeled LDL by the matrix was 62% less (Fig. 4  B, right bar) . Oleic acid did not increase LDL retention. Thus, when LPL was active and/or able to interact with lipoproteins it increased LDL retention. It is likely that prebinding LPL allowed more LPL to associate with the matrix, increasing the amount of LPL available to bind LDL.
VLDL transport and retention. VLDL transport across monolayers of cultured endothelial cells was also assessed in the presence and absence ofLPL. IfLPL was allowed to bind to the cells and VLDL was added, a small (18%) increase in VLDL net transport across the monolayers was found (Fig. 5  A) . No net increase in VLDL transport was observed ifthe LPL and VLDL were mixed before their addition to the upper chamber. Because lipolysis of VLDL produces smaller, remnant lipoproteins, the increase in transport could have resulted from the formation of smaller lipoproteins. However, addition of medium containing a 3:1 molar ratio of oleic acid/BSA also increased VLDL transport by 30%. Thus, even without lipolysis and the generation of smaller lipoproteins, oleic acid increased VLDL transport.
VLDL retention increased when LPL was added to the monolayers. Compared with control conditions, LPL addition produced an eightfold increase in monolayer-associated VLDL (Fig. 5 B) . This increase was most marked when LPL was first bound to the cells rather than added to the cells along with the lipoproteins. Addition of anti-LPL IgG to endothelial cells containing prebound LPL led to a 50% decrease in VLDL retention by the matrix. Although high molar ratios ofoleic acid/ BSA increased VLDL transport, they did not increase VLDL retention. Thus, VLDL retention by the monolayers required LPL and was blocked by an antibody that inhibits VLDL interaction with LPL (23).
Comparison of "2I-labeled LDL and "25-labeled HDL.
Transport and retention of HDL and LDL were compared. In parallel experiments, tracer quantities of 1251-labeled LDL and 1251-labeled HDL in DME containing 10% normolipidemic human serum were added to the apical side of control and LPLtreated (10 ,g/ml) endothelial cell monolayers. At the end of the 1-h incubation, 2.8% of the LDL and 1.4% of the HDL radioactivity was found in the lower chamber. LPL treatment did not alter the amounts of either LDL or HDL tracers transported to the lower chamber. Serum contains more HDL than LDL molecules; therefore, despite the lower percent HDL than LDL radioactivity in the lower chamber, more HDL than LDL was probably transported during the 1-h incubation.
LPL treatment of the monolayers affected only LDL retention. As shown in Figure 6 , LPL treatment caused a more than fourfold increase in retained LDL. LPL treatment also increased the amounts of LPL associated with the endothelial The mechanism responsible for LPL-mediated LDL retention was explored. One possibility is that LPL interaction with LDL leads to LDL aggregation; but, in the presence ofLPL, no marked increase in LDL size assessed by gel filtration (22) and by gradient gel electrophoresis was found. Furthermore, '251-labeled LDL released from LPL-treated matrix appeared similar to control LDL. Therefore, appreciable LDL aggregation was unlikely.
A more likely possibility is that, as illustrated in Fig. 7 , LPL anchors LDL molecules by binding to glycosaminoglycans and to lipoproteins. LPL has separate lipid/lipoprotein-and heparin-binding domains (24) . Because LPL attached to glycosaminoglycans can hydrolyze TG (25), these two domains do not overlap. LPL binds with high affinity to heparan sulfate proteoglycans, including those on the endothelial cell surface and in the subendothelial cell matrix (26) . During hydrolysis of TGrich lipoproteins, LPL is a biochemical bridge between its substrate and proteoglycan binding site. LPL also complexes with LDL. Previous studies from this laboratory (22) and others (27) demonstrated that LPL will associate with LDL-size lipoproteins. Therefore, the biochemical conditions are appropriate for the formation of LPL-LDL complexes that also bind to matrix proteoglycans, including those within the arterial wall. This hypothesis is supported by our (14) studied LDL permeation and retention in normal and atherosclerosis-susceptible areas in the aorta. More LDL was retained by extracellular matrix in the atherosclerosis-prone regions. In contrast, increased LDL permeability of aortic segments was not a consistent feature of atherosclerosis-sensitive sites. Do processes that increase the association of LDL with the extracellular matrix lead to potentially harmful modifications of LDL? Retained LDL may be more easily oxidized due to more prolonged exposure to oxidative enzymes. In addition, proteoglycan-bound LDL is more easily oxidized than LDL in solution (32 (37, 38) . Most ofthis cholesterol originates in circulating LDL (10) or f3-VLDL (39) . Normally the amount of cholesterol within macrophages is tightly regulated. In the presence of LDL, human monocyte-derived macrophages downregulate LDL receptors, preventing cholesteryl ester enrichment of the cells (40, 41) . However, LDL may be modified in the circulation or in the subendothelial cell space to forms that can, in vitro, lead to macrophages enriched in cholesteryl ester. These modifications include LDL lipid oxidation (10, 42) , LDL aggregation (43, 44) , and LDL association with proteoglycans in the extracellular matrix (30, 31) . Although circulating monocytes do not secrete LPL, macrophages (45), including human monocyte-derived macrophages (46), synthesize LPL. We postulate that LPL-mediated LDL retention and LPL hydrolysis ofTG-rich lipoproteins (47) augment conversion ofmacrophages to foam cells. This hypothesis is, however, based on a number ofin vitro findings and requires testing in models that more closely approximate the situation in humans.
